ClinicalTrials.gg
CompletedNCT05638776Updated Sep 28, 2026

Treatment of Chronic Obstructive Pulmonary Disease (COPD) With Diffusion Capacity Defect by REGEND001 Cell Therapy

A Phase 2 interventional study of REGEND001 cell therapy and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Regend Therapeutics. Completed at 8 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Regend Therapeutics · Phase 2, Interventional, and Treatment

Updated Sep 28, 2026Eligibility revisedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Enrollment
208th of 286
58 · median 155
Started
2022
with 25 others
Phase 2
33 of 404
13 open now
Registered
241st of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 208th largest by enrollment of the 286 interventional ones that give a count, is one of 26 that started in 2022, is one of 33 in phase 2, and was the 241st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide with the characterization of obstructed airflow. In a large number of patients, diffusion function is impaired along with the progression of disease. REGEND001 cell therapy, comprised of airway basal cells with ability to regenerate lung tissue, is promising to COPD treatment. In this study, a multicenter, randomized, single-blind, placebo-parallel-controlled trial is performed to assess the efficacy and safety of REGEND001 cell therapy in treatment of chronic obstructive pulmonary disease with diffusion capacity defect.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

The criteria were revised on the registry on Sep 28, 2026. See what changed

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 40 to 75 at the time of signing .
  • Diagnosed with according to the 2021 Global Initiative for Chronic Obstructive Lung Disease (GOLD).
  • The ratio of (FEV1)/forced vital capacity (FVC)FEV1/FVC is \< 70% after inhalation of bronchodilators.
  • The diffusion function of carbon monoxide (DLCO) is ≥ 20% and \< 80% of the predicted value at screening.
  • Tolerated to pulmonary function tests.
  • Tolerated to bronchoscopy
  • Voluntary to sign the informed consent, coordinated to finish the trial-related procedures and tests, and capable of recording or stating the change of disease condition in a relatively complete manner.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, nursing, or planning to be pregnant within a year after using this product (or males whose spouse planning to be pregnant);
  • Subjects with a positive result for any of the following tests at screening: treponema pallidum antibody (TP-Ab), (HIV) antibody, surface antigen (HBsAg), or virus (HCV) antibody. But except the followings:

    1. Hepatitis B virus carriers (only HBsAg positive without any hepatitis symptom or sign, and all liver function tests present normal results or abnormal markers without clinical significance by the assessment of investigators);
    2. Cured hepatitis C patients (negative in HCV ribonucleic acid (RNA) test);
  • Subject with assessed survival time of \< 1 year by investigators at screening;
  • Subject with malignant tumors or a history of malignant tumors at screening;
  • Subject with infections in lung or other sites, requiring intravenous drug treatment within a week prior to screening;
  • Subject with more than 4 moderate-to-severe AECOPD, resulting in hospitalization within a year prior to screening;
  • Subject with one or more pathogenetic or serologic findings of the novel coronavirus infection, or symptoms of suspected infection within 6 weeks prior to screening;
  • Subject with a history of invasive or noninvasive mechanical ventilation within 4 weeks prior to screening;
  • Subject who has taken prednisone tablets orally at a dose of ≥ 20 mg/day (or equivalent amount of other oral ) within 4 weeks prior to screening;
  • Subject with major lung diseases other than by assessment of investigators at screening;
  • Subject with severe systemic diseases other than lung within 6 months prior to screening and assessed to be inappropriate to participate in this trial by investigators;
  • Subject with severe anemia or poorly controlled granulocyte deficiency, thrombocytopenia by assessment of investigators;
  • Subject with abnormal coagulation and assessed to be negative for the safety of fiberoptic bronchoscopy operations at screening;
  • Subject requiring long-term anticoagulation therapy of using antiplatelet coagulant therapeutic agents and disable to discontinue their medications 1 week prior to cell collection and cell infusion as assessed by investigators;
  • Subject with a risk of suicide, a history of mental illness or a history of epilepsy at screening;
  • Subject with severe arrhythmias or heart conduction disorders (degree II or above) in 12-lead test at screening;
  • Subject participated in other clinical trials with interventions within 3 months prior to screening;
  • Investigators, co-investigators, research coordinators, employees of research participants or research centers, or their family members;
  • Any circumstance considered to probably increase the risk of patients or interfere with the clinical trial.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    REGEND001 cell therapy

    REGEND001 cell therapy

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Responsive rate (RR)

    Ratio of subjects responsive to the treatment. Subject is considered to be responsive to the treatment as (1) the lung diffusing capacity for carbon monoxide (DLCO) improvement meets MCID (minimal clinically important difference) at 12 or/and 24 weeks after therapy; and (2) mean of DLCO at 12 and 24 weeks is no less than the baseline value. MCID of DLCO improvement is 1.1 ml/min/mmHg (0.37 mmol·min -1·kPa-1) or 11% for measured value compared to baseline .

    Time frame: 12 weeks after treatment, 24 weeks after treatment

Secondary outcomes

  1. Change of lung diffusing capacity for carbon monoxide (DLCO) from baseline

    DLCO is considered a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.

    Time frame: Within 52 weeks after treatment

  2. Change of the alveolar volume (VA) from baseline

    Alveolar ventilation is the exchange of gas between the alveoli and the external environment. It is the process by which oxygen is brought into the lungs from the atmosphere and by which the carbon dioxide carried into the lungs in the mixed venous blood is expelled from the body.

    Time frame: Winthin 52 weeks after treatment

  3. Change of images of lung by high resolution computed tomography (HR-CT) from baseline

    HR-CT images of lung will be analyzed to indicate the change of pulmonary structure.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  4. Change of forced vital capacity (FVC) from baseline

    FVC is the full amount of air that can be exhaled with effort in a complete breath.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  5. Change of forced expiratory volume in one second (FEV1) from baseline

    FEV1 is the volume of breath exhaled with effort in one second.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  6. Change of forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) from baseline

    The FEV1/FVC is a ratio that reflects the amount of air you can forcefully exhale from your lungs. It's measured by spirometry, a test used to evaluate lung function.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  7. Change of the diffusing capacity for carbon monoxide/ the alveolar volume (DLCO/VA) from baseline

    The DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.Since DLCO is affected by the amount of inhaled gas and lung volume, the subject's alveolar ventilation (VA) is also considered when evaluating diffusion function to exclude the effect of lung volume on diffusion volume.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  8. Change of 6-minute-walk test (6MWT) from baseline

    The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  9. Change of modified medical research council (mMRC) dyspnea scale from baseline

    It is a questionnaire to evaluate how breathlessness impacts daily activities. According to the degree of activity impacted by shortness of breath, mMRC results are divided into 0-4 grades. Grade 0 means no breathlessness except on strenuous exercise; grade 1 means shortness of breath when hurrying on the level or walking up a slight hill; grade 2 means walking slower than people of same age on the level because of breathlessness or having to stop to catch breath when walking at their own pace on the level; grade 3 means stoping for breath after walking ∼100 m or after few minutes on the level ground; and grade 4 means too breathless to leave the house, or breathless when dressing or undressing.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  10. Change of chronic obstructive pulmonary disease Assessment Test (CAT) from baseline

    The CAT is a questionnaire for people with COPD. It is designed to measure the impact of COPD on a person's life, and how this changes over time. The CAT scale includes a total of 8 items, 0\~5 points for each item. The total score ranges 0\~40 points. Score of 0-10 points indicates slight impact; Score of 11-20 points indicates medium impact: Score of 21-30 points indicates serious impact; Score of 31-40 points indicates very serious impact.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  11. Annual frequency of exacerbations

    Frequency of exacerbations all through the year. A lower frequency means improvement of disease.

    Time frame: 1 year after treatment

  12. Symptoms, physical examination

    Number of cases with abnormal physical examination findings.

    Time frame: Baseline, treatment day (D1), 24 hours after treatment, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  13. 12-lead ECG

    Number of cases with abnormal 12-lead Electrocardiogram (ECG).

    Time frame: 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  14. Blood routine

    Number of cases with abnormal laboratory test results.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  15. Urine routine

    Number of cases with abnormal laboratory test results.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  16. Blood biochemistry

    Number of cases with abnormal laboratory test results.

    Time frame: Baseline, 4 weeks after treatment, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  17. Function of blood clotting

    Number of cases with abnormal function of blood clotting.

    Time frame: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  18. Carcinoembryonic antigen (CEA)

    CEA is a tumor marker used for early diagnosis of lung cancer.

    Time frame: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  19. Neuron-specific enolase (NSE)

    NSE is a tumor marker significantly elevated in small cell lung cancer.

    Time frame: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  20. Cytokeratin-19-fragment (CYFRA21-1)

    CYFRA21-1 is a tumor marker which is valuable for the pathological classification and prognosis evaluation of lung cancer.

    Time frame: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

  21. Squamous cell carcinoma antigen (SCC)

    SCC is a specific marker for lung squamous cell carcinoma.Tumor markers are monitored to assess the safety.

    Time frame: Baseline, 12 weeks after treatment, 24 weeks after treatment, 52 weeks after treatment

07

Study locations

8 sites
  • China-Japan Friendship Hospital
    Beijing, Beijing Municipality, China
  • The Southwest Hospital of AMU
    Chongqing, Chongqing Municipality, China
  • The First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality, China
  • Zhongshan Hospital affiliated to Fudan University
    Shanghai, Shanghai Municipality, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Jul 2025, 31 months.

Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 31 months is above that.

Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2022
First posted
Dec 6, 2022
StartActual
Dec 6, 2022
Primary completionActual
Jul 9, 2025
CompletionActual
Jul 9, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedSubjectSubjects with a positive in eachresult for any of the following tests containingat screening: treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at screening. But except the followings:
Sep 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change of lung diffusing capacity for carbon monoxide (DLCO) from baselineNow Responsive rate (RR)Time frame: Within 52 weeks after treatment → 12 weeks after treatment, 24 weeks after treatment
Sep 28, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedChange of lung diffusing capacity for carbon monoxide (DLCO) from baselineTime frame: Within 52 weeks after treatment
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedSubjectSubjects with a positive in eachresult for any of the following tests containingat screening: treponema pallidum antibody (TP-Ab), human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at screening. But except the followings:
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change of lung diffusing capacity for carbon monoxide (DLCO) from baselineNow Responsive rate (RR)Time frame: Within 52 weeks after treatment → 12 weeks after treatment, 24 weeks after treatment
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedChange of lung diffusing capacity for carbon monoxide (DLCO) from baselineTime frame: Within 52 weeks after treatment
    + 1 other change: oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05638776
Lead sponsor
Regend Therapeutics
Collaborators
The First Affiliated Hospital of Guangzhou Medical University, Southwest Hospital, China, Shanghai Zhongshan Hospital, China-Japan Friendship Hospital, Shanghai East Hospital, Regend Therapeutics XLotus (Jiangxi) Co, Ltd., The First Affiliated Hospital of Nanchang University, Xiangya Hospital of Central South University, The First Affiliated Hospital of Soochow University
Responsible party
Sponsor
First posted
Dec 6, 2022
Start date
Dec 6, 2022
Primary completion
Jul 9, 2025
Completion
Jul 9, 2025
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: REGEND001

Start the discussion